Mirae Asset Global Investments Co. Ltd. Acquires 4,270 Shares of IQVIA Holdings Inc. $IQV

Mirae Asset Global Investments Co. Ltd. increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 15.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,455 shares of the medical research company’s stock after acquiring an additional 4,270 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in IQVIA were worth $5,975,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Asset Dedication LLC grew its holdings in shares of IQVIA by 224.0% during the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after acquiring an additional 168 shares during the period. Trust Co. of Toledo NA OH purchased a new stake in IQVIA in the second quarter worth about $39,000. J.Safra Asset Management Corp lifted its holdings in shares of IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 169 shares during the last quarter. Rothschild Investment LLC boosted its position in shares of IQVIA by 85.5% in the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after purchasing an additional 124 shares in the last quarter. Finally, Root Financial Partners LLC purchased a new stake in shares of IQVIA in the 3rd quarter worth approximately $43,000. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

Shares of IQVIA stock opened at $229.93 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock’s fifty day moving average is $230.94 and its 200 day moving average is $208.54. The stock has a market cap of $39.16 billion, a P/E ratio of 31.54, a P/E/G ratio of 2.39 and a beta of 1.36. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Evercore ISI raised their price target on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Finally, Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, January 25th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.06.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.